Towards a cannabinoid hypothesis of schizophrenia: Cognitive impairments due to dysregulation of the endogenous cannabinoid system

Pharmacology Biochemistry and Behavior

Volumn 56, Issue 4, 1997, Pages 803-807

  Emrich, Hinderk M ^a   Leweke, F Markus ^a   Schneider, Udo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

binocular depth inversion; endogenous cannabinoid system; human; perceptual disturbance; psychosis; schizophrenia; 9 THC

Indexed keywords

CANNABINOID RECEPTOR; CANNABIS; DRONABINOL; PSYCHEDELIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPOTHESIS; ILLUSION; INTOXICATION; MALE; NEUROPSYCHOLOGY; PERCEPTION DISORDER; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; VOLUNTEER;

CANNABIS;

EID: 0030972351     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00426-1     Document Type: Article

References (32)

1. Bowers M. B. Jr., Morton J. B. Regional brain catecholamines and metabolites following THC, PCP and MK-801. Prog. Neuropsychopharmacol. Biol. Psychiatry. 18:1994;961-964.
2. Chopra G. S., Smith J. W. Psychotic reactions following cannabis use in East Indians. Arch. Gen. Psychiatry. 30:1974;24-27.
3. Ciaranello R. D., Ciaranello A. L. Genetics of major psychiatric disorders. Annu. Rev. Med. 42:1991;151-158.
4. Crow T. J. Molecular pathology of schizophrenia More than one disease process? Br. Med. J. 280:1980;66-68.
5. Devane W. A., Dysarz F. A. III, Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
6. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
7. Emrich H. M. A three-component-system hypothesis of psychosis. Impairment of binocular depth inversion as an indicator of a functional dysequilibrium. Br. J. Psychiatry. 155:1989;S37-S39.
8. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1964;1646-1647.
9. Gardner E. L., Lowinson J. H. Marijuana's interaction with brain reward systems. Update 1991 Pharmacol. Biochem. Behav. 40:1991;571-580.
10. Gardner E. L., Paredes W., Smith D., Donner A., Milling C., Cohen D., Morrison D. Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol. Psychopharmacology (Berl.). 96:1988;142-144.
11. Halikas J. A., Goodwin D. W., Guze S. B. Marijuana use and psychiatric illness. Arch. Gen. Psychiatry. 27:1972;162-165.
12. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:1993;3032-3034.
13. Heinrich D. W., Buchanan R. W. Significance and meaning of neurological signs in schizophrenia. Am. J. Psychiatry. 145:1988;11-18.
14. Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R., Rice K. C. Characterization and localization of cannabinoid receptors in rat brain. A quantitative in vitro autoradiographic study J. Neurosci. 11:1991;563-583.
15. Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., de Costa B. R., Rice K. C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
16. Hollister L. E. Health aspects of cannabis. Pharmacol. Rev. 38:1986;1-20.
17. King D. J., Wilson A., Cooper S. J., Waddington J. L. The clinical correlates of neurological soft signs in chronic schizophrenia. Br. J. Psychiatry. 158:1991;770-775.
18. Kupfer D. J., Detre T., Koral J., Fajans P. A comment on the "amotivational syndrome" in marijuana smokers. Am. J. Psychiatry. 130:1973;1319-1321.
19. Mailleux P., Vanderhaeghen J. J. Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen. Eur. J. Pharmacol. 266:1994;193-196.
20. Peralta V., Cuesta M. J. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr. Scand. 85:1992;127-130.
21. Rottanburgh D., Robins A. H., Ben-Arie O., Teggin A., Elk R. Cannabis-associated psychosis with hypomanic features. Lancet. 2:1982;1364-1366.
22. 9-Tetrahydrocannabinol facilitates striatal dopaminergic transmission. Pharmacol. Biochem. Behav. 33:1989;397-400.
23. Schneider U., Leweke F. M., Sternemann U., Weber M. M., Emrich H. M. Visual 3D illusion. A systems-theoretical approach to psychosis Eur. Arch. Psychiatry Clin. Neurosci. 246:1996;256-260.
24. Schröder J., Richter P., Geider F. J., Niethammer R., Binkert M., Reitz C., Sauer H. Diskrete motorische und sensorische Störungen (neurologische soft signs) im Akutverlauf endogener Psychosen. Z. Klin. Psychol. Psychopathol. Psychother. 41:1993;190-206.
25. Seeman P., Van Tol H. H. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15:1994;264-270.
26. Spencer D. J. Cannabis induced psychosis. Br. J. Addict. 65:1970;369-372.
27. Szymanski S., Kane J. M., Lieberman J. A. A selective review of biological markers in schizophrenia. Schizophr. Bull. 17:1991;99-111.
28. Täschner K. L. Zur Psychopathologie und Differentialdiagnose sogenannter Cannabispsychosen. Fortschr. Neurol. Psychiatr. 51:1983;235-248.
29. Thacore V. R., Shukla S. R. Cannabis psychosis and paranoid schizophrenia. Arch. Gen. Psychiatry. 33:1976;383-386.
30. Thomas H. Psychiatric symptoms in cannabis users. Br. J. Psychiatry. 163:1993;141-149.
31. Wright I., Woodruff P. Aetiology of schizophrenia. A review of theories and their clinical and therapeutic implications. CNS Drugs. 3:1995;126-144.
32. Andreasson, S.; Allebeck, P.; Rydberg, U.: Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr. Scand. 79:505-510.